Advertisement

Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group

  • Francesco Sclafani
    Correspondence
    Corresponding author at: Francesco Sclafani, Department of Medical Oncology, Institut Jules Bordet, Rue Meylemeersch 90, Anderlecht 1070, Belgium.
    Affiliations
    Department of Medical Oncology, Institut Jules Bordet, Rue Meylemeersch 90, Anderlecht 1070, Belgium

    Université Libre de Bruxelles (ULB), Brussels, Belgium

    European Organisation for Research and Treatment of Cancer, Brussel, Belgium
    Search for articles by this author
  • Elisa Fontana
    Affiliations
    European Organisation for Research and Treatment of Cancer, Brussel, Belgium

    Sarah Cannon Research Institute, London, UK
    Search for articles by this author
  • Lucjan Wyrwicz
    Affiliations
    European Organisation for Research and Treatment of Cancer, Brussel, Belgium

    Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Search for articles by this author
  • Anna Dorothea Wagner
    Affiliations
    European Organisation for Research and Treatment of Cancer, Brussel, Belgium

    Department of Oncology, Division of medical Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
    Search for articles by this author
  • Juan W. Valle
    Affiliations
    European Organisation for Research and Treatment of Cancer, Brussel, Belgium

    Division of Cancer Sciences, University of Manchester, Manchester, UK

    Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
    Search for articles by this author
  • Elizabeth Smyth
    Affiliations
    European Organisation for Research and Treatment of Cancer, Brussel, Belgium

    Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK
    Search for articles by this author
  • Mark Peeters
    Affiliations
    European Organisation for Research and Treatment of Cancer, Brussel, Belgium

    Department of Oncology, Universitair Ziekenhuis Antwerpen, Antwerp, Belgium
    Search for articles by this author
  • Radka Obermannova
    Affiliations
    European Organisation for Research and Treatment of Cancer, Brussel, Belgium

    Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno, Czech Republic

    Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
    Search for articles by this author
  • Cindy Neuzillet
    Affiliations
    European Organisation for Research and Treatment of Cancer, Brussel, Belgium

    Department of Medical Oncology, Institut Curie, Versailles Saint-Quentin University – Paris Saclay University, Saint-Cloud, France
    Search for articles by this author
  • Manfred P. Lutz
    Affiliations
    European Organisation for Research and Treatment of Cancer, Brussel, Belgium

    Caritasklinikum, Saarbrucken, Germany
    Search for articles by this author
  • Thibaud Koessler
    Affiliations
    European Organisation for Research and Treatment of Cancer, Brussel, Belgium

    Department of Oncology, Geneva University Hospital, Geneva, Switzerland

    Swiss Cancer Center Leman (SCCL), University of Geneva, Lausanne, Switzerland
    Search for articles by this author
  • Irit Ben-Aharon
    Affiliations
    European Organisation for Research and Treatment of Cancer, Brussel, Belgium

    Division of Oncology, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel
    Search for articles by this author
  • Dirk Arnold
    Affiliations
    European Organisation for Research and Treatment of Cancer, Brussel, Belgium

    Department of Oncology, Haematology and Palliative Care, AK Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany
    Search for articles by this author
  • Maria Alsina
    Affiliations
    European Organisation for Research and Treatment of Cancer, Brussel, Belgium

    Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Passeig de la Vall d'Hebron, Barcelona, Spain
    Search for articles by this author
  • Markus Moehler
    Affiliations
    European Organisation for Research and Treatment of Cancer, Brussel, Belgium

    Department of Internal Medicine, Johannes-Gutenberg University, Mainz, Germany
    Search for articles by this author
Published:April 22, 2022DOI:https://doi.org/10.1016/j.clcc.2022.04.001

      Abstract

      Recently, we have witnessed impressive diagnostic and therapeutic changes for gastrointestinal cancer patients. New challenges brought by the COVID-19 pandemic have led us to re-evaluate our work priorities. Thanks to the commendable resilience of both investigators and patients, however, clinical research never stopped. In addition to conducting cutting-edge research and serving patients’ needs, as EORTC Gastrointestinal Tract Cancer Group, we are committed to pursuing educational initiatives beneficial to the entire European oncology community and beyond. In this regard, we have been providing critical discussions of new data from major international meetings. In this article, we discuss results of important selected studies presented at the 2022 ASCO Gastrointestinal Cancer Symposium, putting them in perspectives and highlighting potential implications for routine practice. With the number of in-person attendees and practice-changing/informing trials presented, this meeting represented a milestone in the return to normality as well as in the fight against cancer.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Satoh T
        • Xu RH
        • Chung HC
        • et al.
        Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN—a randomized, phase III study.
        J Clin Oncol. 2014; 32: 2039-2049
        • Thuss-Patience PC
        • Shah MA
        • Ohtsu A
        • et al.
        Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
        Lancet Oncol. 2017; 18: 640-653
        • Pietrantonio F
        • Caporale M
        • Morano F
        • et al.
        HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: implication for further clinical research.
        Int J Cancer. 2016; 139: 2859-2864
        • Shitara K
        • Bang YJ
        • Iwasa S
        • et al.
        Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer.
        N Engl J Med. 2020; 382: 2419-2430
        • Yamaguchi K
        • Bang YJ
        • Iwasa S
        • et al.
        Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2–positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).
        J Clin Oncol. 2022; 40: 242
        • Shitara K
        • Bang YJ
        • Iwasa S
        • et al.
        Exploratory analysis of the impact of prior immune checkpoint inhibitor (ICI) on trastuzumab deruxtecan (T-DXd; DS-8201) clinical outcomes and biomarkers (BM) in DESTINY-Gastric01 (DG-01), a randomized, phase 2, multicenter, open-label study in patients (pts) with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma.
        J Clin Oncol. 2020; 38: 322
        • Van Cutsem E
        • Di Bartolomeo M
        • Smyth E
        • et al.
        Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen.
        Ann Oncol. 2021; 32: S1283-S1346
      1. Trastuzumab deruxtecan for subjects with HER2-positive gastric cancer or gastro-esophageal junction adenocarcinoma after progression on or after a trastuzumab-containing regimen (DESTINY-Gastric04). Available at: https://clinicaltrials.gov/ct2/show/NCT04704934?term=destiny+gastric+04&draw=2&rank=1 (Accessed February 20, 2022).

        • Janjigian YY
        • Oh DY
        • Rha SY
        • et al.
        Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.
        J Clin Oncol. 2020; 38: 295
        • Janjigian YY
        • Shitara K
        • Moehler M
        • et al.
        First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
        Lancet. 2021; 398: 27-40
        • Sun JM
        • Shen L
        • Shah MA
        • et al.
        Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
        Lancet. 2021; 398: 759-771
        • Bang YJ
        • Van Cutsem E
        • Fuchs CS
        • et al.
        KEYNOTE-585: phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer.
        Future Oncol. 2019; 15: 943-952
        • Chao J
        • Fuchs CS
        • Shitara K
        • et al.
        Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy.
        J Clin Oncol. 2020; 38: 430
        • Andre T
        • Tougeron D
        • Piessen G
        • et al.
        Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): the GERCOR NEONIPIGA phase II study.
        J Clin Oncol. 2022; 40: 244
        • Golan T
        • Hammel P
        • Reni M
        • et al.
        Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
        N Engl J Med. 2019; 381: 317-327
        • Marabelle A
        • Le DT
        • Ascierto PA
        • et al.
        Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study.
        J Clin Oncol. 2020; 38: 1-10
        • Pishvaian MJ
        • Blais EM
        • Brody JR
        • et al.
        Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial.
        Lancet Oncol. 2020; 21: 508-518
        • Bekaii-Saab TS
        • Spira AI
        • Yaeger R
        • et al.
        KRYSTAL-1: updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation.
        J Clin Oncol. 2022; 40: 519
        • Fu Q
        • Chen Y
        • Huang D
        • et al.
        Randomized phase III study of sintilimab in combination with modified folfrinox versus folfrinox alone in patients with metastatic and recurrent pancreatic cancer in China: the CISPD3 trial.
        J Clin Oncol. 2022; 40: 560
        • Renouf DJ
        • Knox JJ
        • Kavan P
        • et al.
        LBA65 The Canadian Cancer Trials Group PA.7 trial: results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
        Ann Oncol. 2020; 31: S1195
        • Hammel P
        • Fabienne P
        • Mineur L
        • et al.
        Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: an open-label, randomized phase IIb trial.
        Eur J Cancer. 2020; 124: 91-101
        • Hammel P
        • El-Hariry Macarulla T
        • et al.
        Trybeca-1: a randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma (NCT03665441).
        J Clin Oncol. 2022; 40: 518
        • Kordes S
        • Pollak MN
        • Zwinderman AH
        • et al.
        Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.
        Lancet Oncol. 2015; 16: 839-847
        • Van Cutsem E
        • Lenz HJ
        • Furuse J
        • et al.
        MAESTRO: a randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).
        J Clin Oncol. 2016; 34: 4007
        • Finn RS
        • Qin S
        • Ikeda M
        • et al.
        Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.
        N Engl J Med. 2020; 382: 1894-1905
        • Abou-Alfa GK
        • Lam Chan S
        • Kudo M
        • et al.
        Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
        J Clin Oncol. 2022; 40: 379
        • Kelley RK
        • Sangro B
        • Harris W
        • et al.
        Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I/II study.
        J Clin Oncol. 2021; 39: 2991-3001
        • Peng Z
        • Fan W
        • Zhu B
        • et al.
        Lenvatinib combined with transarterial chemoembolization as first-line treatment of advanced hepatocellular carcinoma: a phase 3, multicenter, randomized controlled trial.
        J Clin Oncol. 2022; 40: 380
        • Ikeda M
        • Nakachi K
        • Konishi M
        Adjuvant S-1 versus observation in curatively resected biliary tract cancer: a phase III trial (JCOG1202: ASCOT).
        J Clin Oncol. 2022; 40: 382
        • Primrose JN
        • Fox RP
        • Palmer DH
        • et al.
        Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.
        Lancet Oncol. 2019; 20: 663-673
        • Oh DY
        • He AR
        • Qin S
        • et al.
        A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.
        J Clin Oncol. 2022; 40: 378
        • Valle J
        • Wasan H
        • Palmer DH
        • et al.
        Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
        N Engl J Med. 2010; 362: 1273-1281
        • Morizane C
        • Machida N
        • Honma Y
        • et al.
        Randomized phase III study of etoposide plus cisplatin versus irinotecan plus cisplatin in advanced neuroendocrine carcinoma of the digestive system: a Japan Clinical Oncology Group study (JCOG1213).
        J Clin Oncol. 2022; 40: 501
        • Overman MJ
        • McDermott R
        • Leach JL
        • et al.
        Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.
        Lancet Oncol. 2017; 18: 1182-1191
        • Overman MJ
        • Lonardi S
        • Wong KYM
        • et al.
        Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.
        J Clin Oncol. 2018; 36: 773-779
        • Lenz HJ
        • Van Cutsem E
        • Luisa Limon M
        • et al.
        First-line nivolumab plus ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study.
        J Clin Oncol. 2022; 40: 161-170
        • André T
        • Shiu K-K
        • Kim TW
        • et al.
        Pembrolizumab in microsatellite-instability–high advanced colorectal cancer.
        N Engl J Med. 2020; 383: 2207-2218
        • Cohen R
        • Meurisse A
        • Pudlarz T
        • et al.
        One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): long-term follow-up of the GERCOR NIPICOL phase II study.
        J Clin Oncol. 2022; 40: 13
        • Cohen R
        • Bennouna J
        • Meurisse A
        • et al.
        RECIST and iRECIST criteria for the evaluation of nivolumab + ipilimumab combination in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): results of the GERCOR NIPICOL phase II study.
        J Immunother Cancer. 2020; 8e001499
        • Sclafani F.
        MEK and PD-L1 inhibition in colorectal cancer: a burning blaze turning into a flash in the pan.
        Lancet Oncol. 2019; 20: 752-753
        • Baraibar I
        • Mirallas O
        • Saoudi N
        • et al.
        Combined treatment with immunotherapy-based strategies for MSS metastatic colorectal cancer.
        Cancers (Basel). 2021; 13: 6311
        • Lenz HJ
        • Parikh AR
        • Spigel DR
        • et al.
        Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): phase 2 results from CheckMate 9X8.
        J Clin Oncol. 2022; 40: 8
        • Cremolini C
        • Rossini D
        • Antoniotti C
        • et al.
        FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: results of the phase II randomized AtezoTRIBE study by GONO.
        Ann Oncol. 2021; 32: S1294-S1295
        • Russo M
        • Crisafulli G
        • Sogari A
        • et al.
        Adaptive mutability of colorectal cancers in response to targeted therapies.
        Science. 2019; 366: 1473-1480
        • Morris VK
        • Megerdichian Parseghian C
        • Escano M
        • et al.
        Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer.
        J Clin Oncol. 2022; 40: 12
        • Corcoran RB
        • Giannakis M
        • Allen J
        • et al.
        Clinical efficacy of combined BRAF, MEK and PD-1 inhibition in BRAFV600E colorectal cancer patients.
        Ann Oncol. 2020; 31: S226-S227
        • Kopetz S
        • Grothey A
        • Yaeger R
        • et al.
        Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer.
        N Engl J Med. 2019; 381: 1632-1643
        • Chalabi M
        • Fanchi LF
        • Dijkstra KK
        • et al.
        Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
        Nat Med. 2020; 26: 566-576
        • Ludford K
        • Raghav K
        • Blum Murphy MA
        • et al.
        Neoadjuvant pembrolizumab in localized/locally advanced solid tumors with mismatch repair deficiency.
        Ann Oncol. 2021; 32: S1211-S1226
        • van der Valk MJM
        • Hilling DE
        • Bastiaannet E
        • et al.
        Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study.
        Lancet. 2018; 391: 2537-2545
        • Lumish MA
        • Cohen JL
        • Stadler ZK
        • et al.
        PD-1 blockade alone for mismatch repair deficient (dMMR) locally advanced rectal cancer.
        J Clin Oncol. 2022; 40: 16
        • Seymour MT
        • Thompson LC
        • Wasan HS
        • et al.
        Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
        Lancet. 2011; 277: 1749-1759
        • Cunningham D
        • Lang I
        • Marcuello E
        • et al.
        Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
        Lancet Oncol. 2013; 14: 1077-1085
        • Lonardi S
        • Schirripa M
        • Buggin F
        • et al.
        First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study.
        J Clin Oncol. 2020; 38: 4002
        • Hamaguchi T
        • Takashima A
        • Mizusawa J
        • et al.
        A randomized phase III trial of mFOLFOX7 or CapeOX plus bevacizumab versus 5-FU/l-LV or capecitabine plus bevacizumab as initial therapy in elderly patients with metastatic colorectal cancer: JCOG1018 study (RESPECT).
        J Clin Oncol. 2022; 40: 10
        • Tie J
        • Cohen JD
        • Lo SN
        • et al.
        Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: individual patient pooled analysis of three cohort studies.
        Int J Cancer. 2021; 148: 1014-1026
        • Tie J
        • Wang Y
        • Cohen J
        • et al.
        Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: a prospective cohort study.
        PLoS Med. 2021; 18e1003620
        • Kotaka M
        • Shirasu H
        • Watanabe J
        • et al.
        Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan.
        J Clin Oncol. 2022; 40: 9
        • Sahin U
        • Türeci Ö
        • Manikhas G
        • et al.
        FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
        Ann Oncol. 2021; 32: 609-619
      2. A study of zolbetuximab (IMAB362) plus CAPOX compared with placebo plus CAPOX as first-line treatment of subjects with claudin (CLDN) 18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (GLOW). Available at: https://clinicaltrials.gov/ct2/show/NCT03653507 (Accessed February 21, 2022).

      3. A phase 3 efficacy, safety and tolerability study of zolbetuximab (experimental drug) plus mFOLFOX6 chemotherapy compared to placebo plus mFOLFOX6 as treatment for gastric and gastroesophageal junction (GEJ) cancer (Spotlight). Available at: https://clinicaltrials.gov/ct2/show/NCT03504397 (Accessed February 21, 2022).

        • Gabrail NY
        • Tolcher A
        • Alese OB
        • et al.
        A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors.
        J Clin Oncol. 2022; 40: TPS375
        • Bang YJ
        • Van Cutsem E
        • Feyereislova A
        • et al.
        Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
        Lancet. 2010; 376: 687-697
        • Park H
        • Bekaii-Saab TS
        • Kim SS
        • et al.
        Phase 1b/2, open-label, dose-escalation and expansion trial of tucatinib in combination with trastuzumab with and without oxaliplatin-based chemotherapy or pembrolizumab in patients with unresectable or metastatic HER2+ gastrointestinal cancers.
        J Clin Oncol. 2022; 40: TPS376
        • Stinchcombe T
        • Monk BJ
        • Frances A
        • et al.
        SGNTUC-019: phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations.
        J Clin Oncol. 2022; 40: TPS3151
        • Meric-Bernstam F
        • Anoka CH
        • Dobrowolska A
        • et al.
        A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select human epidermal growth factor receptor 2 (HER2)-expressing solid tumors (DESTINY-PanTumor02).
        J Clin Oncol. 2022; 40: TPS623
        • Reiss KA
        • Yuan Y
        • Barton D
        • et al.
        A phase 1, first-in-human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors.
        J Clin Oncol. 2022; 40: TPS668